Jason Saylor, DO
Family Medicine · Lakeland, FLNPI 1407086846
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $95,330 of the $102,513 with a category attached, or 93.0%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 93.3% of it on its own, with 33 other manufacturers making up the rest. Reporting peaked in 2021 at $28,549 and has fallen 98.6% since, to $405 in 2025. Among family medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 484 payments — averaging $211.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$96K
- Novo Nordisk$884
- AstraZeneca$869
- AbbVie$801
- Supernus Pharmaceuticals, Inc.$551
- Lilly USA, LLC$441
- plus $3K from 28 others
What the payments were for
- Consulting fees$95,33093%
- Travel & lodging$1380%
- Food & beverage$6,9117%
- Education$1330%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 57 | $95,640 |
| Novo Nordisk | 61 | $884 |
| AstraZeneca | 46 | $869 |
| AbbVie(2 entities) | 44 | $801 |
| Supernus Pharmaceuticals, Inc. | 45 | $551 |
| Lilly USA, LLC | 33 | $441 |
| Merck | 26 | $410 |
| Johnson & Johnson | 21 | $374 |
| Boehringer Ingelheim | 23 | $362 |
| Pfizer | 21 | $269 |
| Astellas Pharma US Inc | 14 | $259 |
| Novartis | 11 | $206 |
| Amgen | 12 | $183 |
| Sanofi-aventis U.S. LLC | 9 | $164 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $151 |
| Otsuka America Pharmaceutical, Inc. | 5 | $123 |
| Amarin Pharma, Inc. | 7 | $120 |
| Kowa Pharmaceuticals America, Inc. | 8 | $114 |
| GSK | 6 | $90 |
| Dexcom, Inc. | 5 | $90 |
| Phathom Pharmaceuticals, Inc. | 3 | $69 |
| Bayer | 2 | $61 |
| Vivus LLC | 3 | $55 |
| Exact Sciences | 2 | $53 |
| Tris Pharma Inc | 2 | $37 |
| Abbott | 1 | $21 |
| Halozyme Inc | 1 | $19 |
| Regeneron Healthcare Solutions, Inc. | 1 | $17 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Ironshore Pharmaceuticals Inc. | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $11 |
| Medtronic | 1 | $11 |
| Boston Scientific | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$102,513 in reported general payments places this provider in the 95th percentile of 7,282 family medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 286 | $308,462 |
| MounjaroTirzepatide | 120 | $180,348 |
| OzempicSemaglutide | 143 | $165,870 |
| JardianceEmpagliflozin | 112 | $141,689 |
| XareltoRivaroxaban | 110 | $110,466 |
| FarxigaDapagliflozin Propanediol | 84 | $96,149 |
| RybelsusSemaglutide | 61 | $81,671 |
| JanuviaSitagliptin Phosphate | 67 | $76,467 |
| Nurtec OdtRimegepant Sulfate | 28 | $61,233 |
| OtezlaApremilast | 11 | $54,256 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 53 | $53,403 |
| Tresiba Flextouch U-100Insulin Degludec | 68 | $45,050 |
| TrulicityDulaglutide | 38 | $43,249 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 39 | $32,697 |
| LinzessLinaclotide | 22 | $25,548 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Nurtec Odt | $269 | $369,696314 claims |
| Novo NordiskOzempic, Rybelsus | $884 | $247,541204 claims |
| Lilly USA, LLCMounjaro, Trulicity | $441 | $223,597158 claims |
| Boehringer IngelheimJardiance, Tradjenta, Spiriva Respimat, Stiolto Respimat | $362 | $182,860158 claims |
| Johnson & JohnsonXarelto, Invokana | $374 | $125,133127 claims |
| AstraZenecaFarxiga, Bevespi Aerosphere, Symbicort | $869 | $118,141130 claims |
| MerckJanuvia, Janumet, Janumet Xr | $410 | $109,22596 claims |
| GSKTrelegy Ellipta, Shingrix, Arexvy, Breo Ellipta | $90 | $96,573198 claims |
| AmgenOtezla | $183 | $54,25611 claims |
| AbbVieLinzess, Synthroid | $801 | $35,169135 claims |
| Astellas Pharma US IncMyrbetriq | $259 | $20,99222 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 7,282 family medicine providers in Florida.
Other family medicine in Lakeland
- Noah LeeOakland Park$1.2M
- Angela RosselotBelle Isle$977K
- Richard LappOrlando$702K
- Hal BrownVero Beach$477K
- Lisa EvansBoca Raton$473K
- Giovana Rene CrooksBoca Raton$407K
- Edward BraunSt Petersburg$364K
- Samuel GreenleePensacola$235K
- Kevin FitzgeraldStuart$198K
- Louis KuritzkyGainesville$186K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.